Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially life-threatening condition associated with a high case-fatality rate [1], and holds a high risk of recurrence reaching a cumulative 10-year rate of 30% [2]. In order to treat VTE and prevent recurrences, anticoagulant treatment is required for a period of at least three months in any VTE setting. Treatment can be discontinued thereafter if there is a major transient/reversible risk factor related to the onset of VTE.
